Publication | Open Access

New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines

Pparγ Agonist ActivityBreast OncologyMedicineNew TroglitazoneIncreased Antiproliferative EffectBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyCell BiologyCancer ResearchEndocrine-related Cancer